IE41658B1 - Dispersion for electrophoretic analysis - Google Patents
Dispersion for electrophoretic analysisInfo
- Publication number
- IE41658B1 IE41658B1 IE1894/75A IE189475A IE41658B1 IE 41658 B1 IE41658 B1 IE 41658B1 IE 1894/75 A IE1894/75 A IE 1894/75A IE 189475 A IE189475 A IE 189475A IE 41658 B1 IE41658 B1 IE 41658B1
- Authority
- IE
- Ireland
- Prior art keywords
- particles
- dispersion
- antigen
- indicator
- lymphocytes
- Prior art date
Links
- 239000006185 dispersion Substances 0.000 title claims abstract description 25
- 238000001962 electrophoresis Methods 0.000 title claims description 9
- 239000002245 particle Substances 0.000 claims abstract description 81
- 239000000427 antigen Substances 0.000 claims abstract description 49
- 102000036639 antigens Human genes 0.000 claims abstract description 49
- 108091007433 antigens Proteins 0.000 claims abstract description 49
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000011534 incubation Methods 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 19
- 230000005684 electric field Effects 0.000 claims abstract description 19
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 17
- 229920000126 latex Polymers 0.000 claims abstract description 17
- 239000004816 latex Substances 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims abstract description 6
- 238000002649 immunization Methods 0.000 claims abstract description 6
- 230000003993 interaction Effects 0.000 claims abstract description 6
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract description 6
- 238000005259 measurement Methods 0.000 claims abstract description 5
- 229960001005 tuberculin Drugs 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 14
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 4
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 17
- 239000002609 medium Substances 0.000 description 13
- 238000013508 migration Methods 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000001712 encephalitogenic effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QEPMPXAUMUWNNO-UHFFFAOYSA-N bis(methylsulfanyl)methyl-trimethylsilane Chemical compound CSC(SC)[Si](C)(C)C QEPMPXAUMUWNNO-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000001971 thyroidal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2441536A DE2441536C3 (de) | 1974-08-30 | 1974-08-30 | Diagnostisches Verfahren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE41658L IE41658L (en) | 1976-02-29 |
| IE41658B1 true IE41658B1 (en) | 1980-02-27 |
Family
ID=5924452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1894/75A IE41658B1 (en) | 1974-08-30 | 1975-08-29 | Dispersion for electrophoretic analysis |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4081241A (en:Method) |
| JP (1) | JPS521015A (en:Method) |
| AT (1) | AT352901B (en:Method) |
| AU (1) | AU498771B2 (en:Method) |
| BE (1) | BE832960A (en:Method) |
| CA (1) | CA1059902A (en:Method) |
| CH (1) | CH614049A5 (en:Method) |
| DD (1) | DD120716A5 (en:Method) |
| DK (1) | DK144543C (en:Method) |
| FR (1) | FR2282845A1 (en:Method) |
| GB (1) | GB1520279A (en:Method) |
| IE (1) | IE41658B1 (en:Method) |
| IL (1) | IL48007A (en:Method) |
| IT (1) | IT1055851B (en:Method) |
| LU (1) | LU73267A1 (en:Method) |
| NL (1) | NL7510009A (en:Method) |
| SE (1) | SE415401B (en:Method) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2546166A1 (de) * | 1975-10-15 | 1977-04-28 | Behringwerke Ag | Gegerbte thrombozyten |
| DE2750521A1 (de) * | 1977-11-11 | 1979-05-17 | Behringwerke Ag | Diagnostisches verfahren |
| US4222744A (en) * | 1978-09-27 | 1980-09-16 | Becton Dickinson & Company | Assay for ligands |
| FI800724A7 (fi) * | 1979-03-15 | 1981-01-01 | Ciba Geigy Ag | Diagnoosimenetelmä ja varusteet sen suorittamiseksi. |
| US4472506A (en) * | 1981-01-13 | 1984-09-18 | Liburdy Robert P | Method for determining cell membrane dielectric breakdown |
| US4368423A (en) * | 1981-01-13 | 1983-01-11 | Liburdy Robert P | Apparatus for determining cell membrane dielectric breakdown |
| US4436824A (en) | 1981-06-09 | 1984-03-13 | Ortho Diagnostic Systems, Inc. | Leukocyte migration through antigen containing agaroses for immunocompetence testing |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826613A (en) * | 1973-03-06 | 1974-07-30 | Us Navy | Detection and titration of viruses and antibodies using latex |
| US3914400A (en) * | 1973-05-21 | 1975-10-21 | Us Health | Stable antigen-erythrocytes for measuring antibodies against toxoplasma organism |
| US3999944A (en) * | 1975-02-28 | 1976-12-28 | Hoffmann-La Roche Inc. | Detection of breast cancer |
| US3988115A (en) * | 1975-09-18 | 1976-10-26 | Modabber Farrokh Z | Diagnostic method for determining pathological condition by antigen-combining capacity of lymphocytes |
| US3984533A (en) * | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
-
1975
- 1975-05-28 IT IT26703/75A patent/IT1055851B/it active
- 1975-08-25 NL NL7510009A patent/NL7510009A/xx not_active Application Discontinuation
- 1975-08-27 CH CH1110975A patent/CH614049A5/xx not_active IP Right Cessation
- 1975-08-28 AU AU84355/75A patent/AU498771B2/en not_active Expired
- 1975-08-28 DD DD188070A patent/DD120716A5/xx unknown
- 1975-08-28 LU LU73267A patent/LU73267A1/xx unknown
- 1975-08-28 GB GB35528/75A patent/GB1520279A/en not_active Expired
- 1975-08-28 SE SE7509591A patent/SE415401B/xx unknown
- 1975-08-28 IL IL48007A patent/IL48007A/xx unknown
- 1975-08-28 US US05/608,704 patent/US4081241A/en not_active Expired - Lifetime
- 1975-08-29 IE IE1894/75A patent/IE41658B1/en unknown
- 1975-08-29 DK DK390575A patent/DK144543C/da not_active IP Right Cessation
- 1975-08-29 AT AT669075A patent/AT352901B/de not_active IP Right Cessation
- 1975-08-29 CA CA234,613A patent/CA1059902A/en not_active Expired
- 1975-08-29 JP JP50104832A patent/JPS521015A/ja active Pending
- 1975-09-01 FR FR7526773A patent/FR2282845A1/fr active Granted
- 1975-09-01 BE BE159650A patent/BE832960A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE7509591L (sv) | 1976-03-01 |
| BE832960A (fr) | 1976-03-01 |
| SE415401B (sv) | 1980-09-29 |
| IL48007A0 (en) | 1975-11-25 |
| DD120716A5 (en:Method) | 1976-06-20 |
| AU8435575A (en) | 1977-03-03 |
| IE41658L (en) | 1976-02-29 |
| DK144543B (da) | 1982-03-22 |
| GB1520279A (en) | 1978-08-02 |
| CH614049A5 (en:Method) | 1979-10-31 |
| JPS521015A (en) | 1977-01-06 |
| IL48007A (en) | 1979-03-12 |
| US4081241A (en) | 1978-03-28 |
| IT1055851B (it) | 1982-01-11 |
| DK144543C (da) | 1982-09-06 |
| FR2282845A1 (fr) | 1976-03-26 |
| CA1059902A (en) | 1979-08-07 |
| AU498771B2 (en) | 1979-03-22 |
| LU73267A1 (en:Method) | 1977-04-15 |
| FR2282845B1 (en:Method) | 1979-05-25 |
| DK390575A (da) | 1976-03-01 |
| ATA669075A (de) | 1979-03-15 |
| NL7510009A (nl) | 1976-03-02 |
| AT352901B (de) | 1979-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dayer et al. | Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. | |
| Nadel et al. | Immunocytochemical localization of arachidonate 15-lipoxygenase in erythrocytes, leukocytes, and airway cells. | |
| US3915805A (en) | Quantitative detection of endotoxin in biological fluids | |
| Oldham et al. | Cellular microcytotoxicity in human tumor systems: Analysis of results | |
| Code | Histamine in blood | |
| Corash et al. | Heterogeneity of human whole blood platelet subpopulations. III. Density-dependent differences in subcellular constituents | |
| Dean et al. | Functional activities of rosette separated human peripheral blood leukocytes | |
| CA1052245A (en) | Detection of breast cancer | |
| Friedhoff et al. | Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density | |
| Morales et al. | Clinical application of a whole blood assay for human natural killer (NK) cell activity | |
| US4081241A (en) | Diagnostic process | |
| US4311686A (en) | Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis | |
| Goldman et al. | Concanavalin A mediated attachment and ingestion of red blood cells by macrophages | |
| Hopper et al. | The differentiation of T-lymphocytes: III. The behaviour of subpopulations of mouse thymus cells in short-term cell culture | |
| Cowan et al. | Platelet adherence to collagen: role of plasma, ADP, and divalent cations | |
| Yamada et al. | Induction of differentiation of mouse myeloid leukemia cells by poly (ADP-ribose) | |
| Capsoni et al. | A new simplified single-filter assay for ‘in vitro’evaluation of chemotaxis of 51Cr-labeled polymorphonuclear leukocytes | |
| CN102144165B (zh) | 一种刺激细胞的标准样品 | |
| Russo et al. | Studies with biotinylated RBC:(1) use of flow cytometry to determine posttransfusion survival and (2) isolation using streptavidin conjugated magnetic beads | |
| Van Eden et al. | Low T lymphocyte responsiveness to Mycobacterium leprae antigens in association with HLA-DR3 | |
| Day et al. | Report of the working party on platelets | |
| CN106199005A (zh) | 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法 | |
| Elkon et al. | Evaluation of heat-damaged and EgG-coated red cells for testing reticuloendothelial function | |
| Ketchel et al. | The influence of a plasma factor on in vitro leucocyte migration | |
| Hanisch et al. | Quantitative micro-adhesion assay on polystyrene matrices |